arrow
C

Christelle Lévy

centre francois baclesse
H指数:46
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development and validation of a predictive model of aromatase inhibitor-induced arthralgia among patients with early breast cancer

早期乳腺癌患者中芳香化酶抑制剂诱导的关节痛预测模型的开发与验证

2026-08-180
PRE
Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort

老年与年轻HR阳性HER2阴性转移性乳腺癌女性患者真实世界多中心法国ESME队列中的近期治疗与生存趋势

2025-12-050
PRE
18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study

18F-Fluorodeoxyglucose PET-CT评估在完成一周期新辅助治疗后无法预测HER2+BC患者的pCR:一项前瞻性、多中心法国研究

2025-12-030
OAAI
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03

纳武利尤单抗联合伊匹木单抗与卡培他滨作为新辅助化疗后仍有残留病灶的三阴性乳腺癌患者的术后治疗:一项多中心、随机、开放标签的II期试验——BREASTIMMUNE-03

2025-11-210
OAAI
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

CDK4/6抑制剂治疗后疾病进展的HR阳性/HER2阴性转移性乳腺癌患者中真实世界的治疗模式与疗效:ESME-MBC队列研究

2025-09-170
PREAI
Interaction between APOE ε4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study

Apoeε4状态、化疗和内分泌治疗对乳腺癌幸存者认知功能的影响: cantocog纵向研究

2025-02-190
OAAI
Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy

早期乳腺癌接受新辅助化疗后,初始肿瘤负荷与病理完全缓解概率在分子亚型中的关系

2024-09-010
PRE
Trajectories and predictors of peripheral neuropathy after neoadjuvant chemotherapy in a prospective cohort of 11,014 patients with early breast cancer
2024-05-020
PRE
Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC)
2024-05-020
PRE
Prognosis and clinicopathological characteristics of HER2-negative metastatic breast cancers with low expression of hormone receptors: real world evidence from the French ESME cohort
2024-05-020
PRE
Association of clonal hematopoiesis (CH) with clinical outcomes among survivors of breast cancer (BC)
2024-05-020
PRE
Impact of hormone receptor expression level in HR+/HER2-metastatic breast cancer in the large French ESME cohort
2024-05-020
PRE
Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study
2024-05-022
PRE
Prognostic stratification ability of the CPS plus EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
2024-05-012
OA
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2+BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
2024-03-070
OAAI